Rxsight Inc
NASDAQ:RXST

Watchlist Manager
Rxsight Inc Logo
Rxsight Inc
NASDAQ:RXST
Watchlist
Price: 33.66 USD -11.86% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Rxsight Inc?
Write Note

Net Margin
Rxsight Inc

-23.9%
Current
-108%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.9%
=
Net Income
-30.7m
/
Revenue
128.3m

Net Margin Across Competitors

Country US
Market Cap 1.4B USD
Net Margin
-24%
Country JP
Market Cap 6.9T JPY
Net Margin
24%
Country CH
Market Cap 37.7B CHF
Net Margin
12%
Country DK
Market Cap 179.1B DKK
Net Margin
19%
Country US
Market Cap 15.8B USD
Net Margin
11%
Country CN
Market Cap 52B CNY
Net Margin
42%
Country CA
Market Cap 6.3B USD
Net Margin
-8%
Country KR
Market Cap 9.1T KRW
Net Margin
-358%
Country US
Market Cap 6.2B USD
Net Margin
29%
Country US
Market Cap 5.7B USD
Net Margin
9%
Country UK
Market Cap 4.5B GBP
Net Margin
7%
No Stocks Found

Rxsight Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.

RXST Intrinsic Value
14.51 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.9%
=
Net Income
-30.7m
/
Revenue
128.3m
What is the Net Margin of Rxsight Inc?

Based on Rxsight Inc's most recent financial statements, the company has Net Margin of -23.9%.